Ítem
Solo Metadatos

Colesevelam improved lipoprotein particle subclasses in patients with prediabetes and primary hyperlipidaemia

Mostrar el registro sencillo de la publicación
dc.creatorGoldberg, Ronald Bspa
dc.creatorRosenson, Robert Sspa
dc.creatorHernandez-Triana, Ericspa
dc.creatorMisir, Soamnauthspa
dc.creatorJones, Michael Rspa
dc.date.accessioned2020-05-26T00:05:59Z
dc.date.available2020-05-26T00:05:59Z
dc.date.created2013spa
dc.description.abstractBackground: A randomised, double-blind, placebo-controlled study evaluated lipid- and glucose-lowering effects of colesevelam in patients with prediabetes and primary hyperlipidaemia. We report the effect of colesevelam on lipoprotein particle concentration and particle size (determined by nuclear magnetic resonance spectroscopy) in these patients. Methods: Adults with prediabetes (World Health Organization criteria), low-density lipoprotein cholesterol(LDL-C) ? 100 mg/dL (?2.6 mmol/L) and triglycerides less than 500 mg/dL ( less than 5.6 mmol/L) were randomised to colesevelam 3.75 g/day or placebo for 16 weeks. The intent-to-treat population comprised 103 colesevelam and 106 placebo recipients. Results: At the end of the study, mean reduction from baseline in total LDL particle concentration was significantly greater with colesevelam versus placebo (mean treatment difference: ?113 nmol/L; p = 0.02). Increases in total very low-density lipoprotein particle concentration (VLDL-P) and high-density lipoprotein particle concentration (HDL-P) did not differ significantly between the groups; however, with colesevelam versus placebo, there were significantly (p less than 0.05) greater increases in large and medium VLDL-P and large HDL-P and reductions in small VLDL-P. Mean size increases were significantly greater with colesevelam for VLDL (mean treatment difference: 5.3 nm; p less than 0.0001) and HDL (0.1 nm; p = 0.002). Conclusions: Colesevelam improved the overall atherogenic lipoprotein profile in adults with prediabetes and primary hyperlipidaemia, despite potentially less favourable changes in VLDL particles. © The Author(s) 2012.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1177/1479164112461657
dc.identifier.issn14791641
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/23847
dc.language.isoengspa
dc.relation.citationEndPage262
dc.relation.citationIssueNo. 3
dc.relation.citationStartPage256
dc.relation.citationTitleDiabetes and Vascular Disease Research
dc.relation.citationVolumeVol. 10
dc.relation.ispartofDiabetes and Vascular Disease Research, ISSN:14791641, Vol.10, No.3 (2013); pp. 256-262spa
dc.relation.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84876038812&doi=10.1177%2f1479164112461657&partnerID=40&md5=fc9033f028a90944f89390f4f59b3cbcspa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordColesevelamspa
dc.subject.keywordHigh density lipoproteinspa
dc.subject.keywordLipoproteinspa
dc.subject.keywordLow density lipoproteinspa
dc.subject.keywordLow density lipoprotein cholesterolspa
dc.subject.keywordTriacylglycerolspa
dc.subject.keywordVery low density lipoproteinspa
dc.subject.keywordArticlespa
dc.subject.keywordAtherogenesisspa
dc.subject.keywordCardiovascular riskspa
dc.subject.keywordCholelithiasisspa
dc.subject.keywordCholesterol blood levelspa
dc.subject.keywordControlled studyspa
dc.subject.keywordCystocelespa
dc.subject.keywordDrug efficacyspa
dc.subject.keywordDrug safetyspa
dc.subject.keywordErectile dysfunctionspa
dc.subject.keywordFemalespa
dc.subject.keywordHumanspa
dc.subject.keywordHyperlipidemiaspa
dc.subject.keywordHypoglycemiaspa
dc.subject.keywordImpaired glucose tolerancespa
dc.subject.keywordIntention to treat analysisspa
dc.subject.keywordLipoprotein blood levelspa
dc.subject.keywordMajor clinical studyspa
dc.subject.keywordMalespa
dc.subject.keywordNuclear magnetic resonance spectroscopyspa
dc.subject.keywordOral glucose tolerance testspa
dc.subject.keywordOvary polycystic diseasespa
dc.subject.keywordParticle sizespa
dc.subject.keywordPatient preferencespa
dc.subject.keywordRandomized controlled trial (topic)spa
dc.subject.keywordTriacylglycerol blood levelspa
dc.subject.keywordAdultspa
dc.subject.keywordAllylaminespa
dc.subject.keywordCholesteroleng
dc.subject.keywordConstipationspa
dc.subject.keywordDiarrheaspa
dc.subject.keywordDouble-blind methodspa
dc.subject.keywordDyspepsiaspa
dc.subject.keywordFemalespa
dc.subject.keywordHumansspa
dc.subject.keywordHydroxymethylglutaryl-coa reductase inhibitorsspa
dc.subject.keywordHyperlipidemiasspa
dc.subject.keywordIntention to treat analysisspa
dc.subject.keywordLipoproteinsspa
dc.subject.keywordLipoproteinseng
dc.subject.keywordLipoproteinseng
dc.subject.keywordMalespa
dc.subject.keywordNuclear magnetic resonanceeng
dc.subject.keywordParticle sizespa
dc.subject.keywordPrediabetic statespa
dc.subject.keywordTriglyceridesspa
dc.subject.keywordApolipoproteinspa
dc.subject.keywordColesevelamspa
dc.subject.keywordLipoprotein particlesspa
dc.subject.keywordLow-density lipoproteinspa
dc.subject.keywordPrediabetesspa
dc.subject.keywordPrimary hyperlipidaemiaspa
dc.titleColesevelam improved lipoprotein particle subclasses in patients with prediabetes and primary hyperlipidaemiaspa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Colecciones
Artículos